Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
synthetic lethality
Biotech
AstraZeneca's ph. 3 cancer fail is latest blow to ATR inhibitors
The failure is another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs.
Nick Paul Taylor
Dec 22, 2025 4:35am
GSK initiates breakup with Ideaya, hands back 2 programs
Dec 9, 2025 7:15am
Boehringer slots synthetic lethal program into oncology pipeline
Apr 23, 2025 7:45am
Zentalis lays off 40% to fund registrational trial of WEE1 drug
Jan 29, 2025 4:42am
BeiGene inks $150M deal to follow cancer trail blazed by Amgen
Dec 13, 2024 9:11am
Tango axes PRMT5 inhibitor, shifts focus to 2 sibling molecules
Nov 6, 2024 8:28am
